BDRX VS NVO Stock Comparison

Performance

BDRX
10/100

BDRX returned -98.01% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NVO
100/100

NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.

Volatility

BDRX
71/100

BDRX has had a higher than average amount of volatility over the last 12 months giving it a score of 71 of 100.

NVO
53/100

NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Analyst Price Targets

BDRX

"Analyst Price Targets" not found for BDRX

NVO
50/100

1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.

Technicals

BDRX

"Technicals" not found for BDRX

NVO
50/100

NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

BDRX

"Earnings" not found for BDRX

NVO
46/100

NVO has missed earnings 3 times in the last 20 quarters.

Profit

BDRX

"Profit" not found for BDRX

NVO
90/100

Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.

All score calculations are broken down here to help you make more informed investing decisions

Biodexa Pharmaceuticals plc American Depositary Shs Summary

Nasdaq / BDRX

Healthcare

Biotechnology

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Novo-Nordisk A/S Summary

New York Stock Exchange / NVO

Healthcare

Biotechnology

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Power up your portfolio